Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 PandemicCovid-19 Pandemic에 대한 빠른 반응의 일환으로 뉴질랜드 AoTearoa 뉴질랜드의 첫 번째 SARS-COV-2 분리주의 특성Article Published on 2022-02-102022-09-01 Journal: Viruses [Category] COVID19(2023년), Fulltext, MERS, SARS, 변종, 진단, 치료제, [키워드] (molnupiravir analyzed Antiviral Antiviral strategies assays B.1 cells characterization characterized complementary country COVID-19 COVID-19 pandemic COVID-19 vaccine development cultures Cytopathic effect D614G substitution death deep sequencing diagnostic electron microscopy Favipiravir globe growth identity immunofluorescence indirect immunofluorescence initial Ion isolate Isolation Microscopy MiSeq molnupiravir monoclonal antibody nasopharyngeal sample National New New Zealand outbreak pandemic Part platform Rapid Remdesivir Research response responsible RT-qPCR SARS-CoV-2 SARS-CoV-2 isolate SARS-CoV-2 isolates SARS-CoV-2 variant SARS-CoV-2 variants sequence Seven spike glycoprotein Spread susceptible Transmissibility Vero Vero Cell Vero cells Viral virus virus isolate viruses were used western blot whole-genome sequences whole-genome sequencing wild-type [DOI] 10.3390/v14020366 PMC 바로가기 [Article Type] Article
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients입원하지 않은 환자의 코로나19 경구 치료용 몰누피라비르Clinical Trial Published on 2022-02-102022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval active against acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse event adverse events All participants Analysis Antiviral assigned baseline baseline characteristics conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 illness death demonstrated diabetes died double-blind early treatment Efficacy and safety efficacy end point end point Enrollment evaluate event Evidence evidence of Hospitalization Hospitalized Imbalance in some incidence interim analysis laboratory-confirmed Mild-to-moderate molnupiravir New oral participant Patient Phase 3 Placebo placebo group placebo-controlled trial progression randomization Randomized Randomly receive reduce reduced reported Result risk risk factor SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 illness Sex Sharp Subgroup analyses subgroups Symptom the placebo group Treatment Trial two groups Viral load was performed [DOI] 10.1056/NEJMoa2116044 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation StudyPharmacology Published on 2022-02-092022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] Alter antiviral drug antiviral therapy Antiviral treatment changes in characterized clinical trial correlated COVID–19 different time point Effectiveness Efficacy EIDD-2801 experimental drug greater transmissibility Hydroxychloroquine include Infection inhibiting viral replication initial initiated less mathematical disease modeling modeling molnupiravir Mutagenesis Paxlovid Pharmacometrics post inoculation post-hoc analysis Prophylactic Reproduction number SARS-COV-2 infection SARS-CoV-2 variants SARS–CoV-2 variants Simulation susceptibility susceptible Total Transmissibility transmissible variant Treatment Vaccine variant variants of concern variants of concern (VOCs) viral kinetic modelling Viral load viral mutation VoC VOCs was reduced while wild type [DOI] 10.3389/fphar.2022.816429 PMC 바로가기 [Article Type] Pharmacology
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2 Research Published on 2022-02-072022-10-05 Journal: Nature [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] amplified Antiviral antiviral activity antiviral drugs antiviral nucleoside analogue antiviral therapeutics antivirals approved candidate clinically COVID-19 death develop drug effort evade flu-like symptoms Host human respiratory cell identify in vitro in vivo individual Infection inhibit inhibitor Live virus molnupiravir nucleoside analogue Nucleoside analogues Remdesivir replicate RNA virus SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus screened strain subset threat Vaccine Vaccines variant [DOI] 10.1038/s41586-022-04482-x [Article Type] Research
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysisCovid-19에 대한 3 가지 새로운 경구 항 바이러스 처리 (Molnupiravir, Fluvoxamine 및 Paxlovid)의 효능 및 안전성 : 메타 분석Meta-Analysis Published on 2022-02-042022-09-10 Journal: Annals of Medicine [Category] COVID19(2023년), Fulltext, SARS, 치료제, [키워드] (molnupiravir 95% confidence interval addition adverse event adverse events Antiviral antiviral drug antiviral drugs Antiviral treatment antivirals article available data Cochrane Library conducted control group coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 patients COVID-19 research died drug effective eight Epidemic evaluate exhibiting fluvoxamine Guidance Hospitalization Hospitalized Meta-analysis molnupiravir Mortality Occurrence Odds ratio Patient patients with COVID-19 Paxlovid Paxlovid™ placebo group reduced reducing Result retrieved screened searched shown therapeutic effect therapeutic effects treatment for COVID-19 Web of Science [DOI] 10.1080/07853890.2022.2034936 PMC 바로가기 [Article Type] Meta-Analysis
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernRemdesivir, Molnupiravir 및 Nirmatrelvir는 SARS-Cov-2 Omicron 및 기타 변형에 대해 계속 활성화되어 있습니다.Article Published on 2022-02-012022-09-10 Journal: Antiviral Research [Category] 변종, 치료제, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant Delta variants determined by EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging Highlights in vitro Infection molnupiravir MPro Nirmatrelvir nucleoside observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution serial dilutions susceptible target gene Target genes target protein target proteins variants variants of concern Viral Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysisCOVID19 전염병 동안 18개월 동안 대량 사용 후 SARS-COV-2 게놈에서 매우 낮은 수준의 렘데시비르 내성: GISAID 탐색 분석Article Published on 2022-02-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] Analysis Antiviral Antiviral compound Antiviral compounds controlled trials COVID-19 COVID19 E802D Efficacy effort Emergency use authorization Exploratory analysis fitness Frequency Genome GISAID GISAID database hospitalized patients In vitro studies in vivo inhibitor massive molnupiravir mutations Nsp12 pandemic Randomized controlled trial Randomized controlled trials RdRP RdRp mutation RdRp mutations Remdesivir resistance reveal RNA RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 sequencing Strains Viral RNA viral RNA-dependent RNA polymerase [DOI] 10.1016/j.antiviral.2022.105247 PMC 바로가기 [Article Type] Article
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19몰누피라비르 사용에 대한 업데이트된 실제 지침 및 COVID-19 치료를 위한 긴급 사용 승인을 받은 약제와의 비교Clinical Trial Published on 2022-02-012022-09-11 Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), SARS, 변종, 비임상, 신약개발, 임상, 치료법, 치료제, [키워드] 95% CI antiviral drug appear Bamlanivimab–etesevimab breath Casirivimab–imdevimab confidence interval Course COVID-19 COVID-19 patient database death effective Emergency use authorization EUA Google Scholar Hospital admission Hospitalization increased risk India medRxiv molnupiravir Nirmatrelvir Nirmatrelvir-ritonavir number onset of symptoms P-value patients with COVID-19 people with COVID-19 phase 3 study Prevent reduction in Relative risk Remdesivir reported risk risk difference risk reduction Ritonavir Safe SARS-CoV-2 searched severity Side effects Sotrovimab systematic review treat Treatment USA with COVID-19 [DOI] 10.1016/j.dsx.2022.102396 PMC 바로가기 [Article Type] Clinical Trial
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernArticle Published on 2022-02-012022-10-27 Journal: Antiviral Research [Category] COVID-19, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging in vitro Infection molnupiravir MPro Nirmatrelvir observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution susceptible target gene target protein variants of concern Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernArticle Published on 2022-02-012022-10-27 Journal: Antiviral Research [Category] Coronavirus, COVID-19, COVID19(2023년), Fulltext, SARS, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging in vitro Infection molnupiravir MPro Nirmatrelvir observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution susceptible target gene target protein variants of concern Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article